Cancer 360 Alerts
ORM has partnered with Oncology Metrics to produce the only market analyses regarding the economic impact oncology compounds have on payers, providers and patients. Analyses generated are quarterly and include specific products (chemotherapy, biologics, and supportive care) within specific tumors, demonstrating how a given product is positioned economically versus competitors within that tumor.
Reports on Hospital Management of Outpatient Cancer Treatment Decisions
ORM has surveyed almost 100 hospitals regarding the degree to which they are creating preferred cancer treatment guidelines; the resources and criteria used in creating these pathways; which tumors are of greatest concern; how specific products within breast cancer, NSCLC, colorectal cancer and renal cell carcinoma are managed; and how agressively hospitals anticipate future controls will be.
Oncology Account Manager Customer Feedback
ORM produces an annual report that provides insights gathered in Q2 and Q3 regarding what payers, CAC members, state society leaders, and other key players expect and value from oncology account managers when making product access/reimbursement decisions. Pharmaceutical companies will learn specifically where they and their account managers stand relative to these expectations, as well as which demonstrated behaviors led to customers' assessments.
340B Price Discounts
ORM provides an overview of current 340B pricing discounts and projections into the future. What is driving the growth? How big will it get? What can be done to control it? The current 340B environment is analyzed and described, based on assessment of the views of program administrators, pharmaceutical companies, hospitals, specialty practices, payers, and patients. Key growth drivers are analyzed and potential future scenarios described, along with the most likely scenarios. Solutions that can potentially control the growth of 340B pricing discounts are discussed.